Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

HIV/AIDS

Quick Links

Veterans Crisis Line Badge
My healthevet badge

Table 8. Virologic Response Rates in the APRICOT Study

for Health Care Providers

Table 8. Virologic Response Rates in the APRICOT Study

Back to Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults

INF alfa-2a 3 MIU. tiw + RBV 800 mg/day x 48 wkPeg INF alfa-2a (PEGASYS) 180 µg/wk + placebo x 48 wk Peg INF alfa-2a (PEGASYS) 180 µg/wk + RBV 800 mg/day x 48 wk
*p = 0.0078 versus IFN + RBV; ** p < 0.0001 versus IFN + RBV, p < 0.0001 versus PEG only.
n = 285n = 286n = 289
ETR (Overall)14%33%49%
Genotype 18%21%38%
Non-Genotype 1 27% 57%64%
SVR (Overall)12%20%*40%**
Genotype 17%14%29%
Non-Genotype 1 20% 36% 62%

From Management and Treatment of Hepatitis C Virus Infection in HIV-Infected Adults
Hepatitis C Resource Center Program and National Hepatitis C Program Office
September 2005